Comparative Effectiveness of Biosimilar, Reference Product and Other Erythropoiesis-Stimulating Agents (ESAs) Still Covered by Patent in Chronic Kidney Disease and Cancer Patients: An Italian Population-Based Study
about
Prevalence of Use and Cost of Biological and Non-Biological Targeted Therapies for Cancer Treatment: A 5-Year Picture from Southern Italy.Comparing safety information of biosimilars with their originators: a cross-sectional analysis of European risk management plans.Effectiveness of Switch to Erythropoiesis-Stimulating Agent (ESA) Biosimilars versus Maintenance of ESA Originators in the Real-Life Setting: Matched-Control Study in Hemodialysis Patients.Epoetin Biosimilars in the Treatment of Renal Anemia: What Have We Learned from a Decade of European Experience?
P2860
Comparative Effectiveness of Biosimilar, Reference Product and Other Erythropoiesis-Stimulating Agents (ESAs) Still Covered by Patent in Chronic Kidney Disease and Cancer Patients: An Italian Population-Based Study
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Comparative Effectiveness of B ...... Italian Population-Based Study
@ast
Comparative Effectiveness of B ...... Italian Population-Based Study
@en
type
label
Comparative Effectiveness of B ...... Italian Population-Based Study
@ast
Comparative Effectiveness of B ...... Italian Population-Based Study
@en
prefLabel
Comparative Effectiveness of B ...... Italian Population-Based Study
@ast
Comparative Effectiveness of B ...... Italian Population-Based Study
@en
P2093
P2860
P1433
P1476
Comparative Effectiveness of B ...... Italian Population-Based Study
@en
P2093
Achille P Caputi
Alessandro Chinellato
Angela Alibrandi
Armando A Genazzani
Francesco Giorgianni
Gianluca Trifirò
Ilaria Marcianò
Jenny Bolcato
Roberta Pirolo
Valentina Ientile
P2860
P304
P356
10.1371/JOURNAL.PONE.0155805
P407
P577
2016-05-17T00:00:00Z